This underscores the enhanced discriminatory power gained by integrating multiomic biomarker data, especially compared with previously observed performance for CA125 alone of just 76% in distinguishing early-stage ovarian cancer from benign tumors (33). The gene discussed is MUC16; the disease is benign neoplasm.